TumorGen
Pre-clinicalTargeting the rare and deadly circulating metastatic cell clusters (MCCs) is the key in stopping cancer’s spread.
Founded
2018
Focus
OncologyDiagnostics
About
Targeting the rare and deadly circulating metastatic cell clusters (MCCs) is the key in stopping cancer’s spread.
Funding History
1Total raised: $393K
Grant$393KNCIJul 22, 2021
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile